Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 012 • 2020 Pediatric Rheumatology Symposium
Pediatric Antiphospholipid Syndrome: Clinical Features and Therapeutic Interventions in a Series of 22 Cases
Jacqueline Madison¹ and Jason Knight ¹, ¹University of Michigan, Ann Arbor
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory disease classically defined by the presence of circulating antiphospholipid antibodies and either thrombotic events or pregnancy morbidity.…
Abstract Number: 305 • 2019 ACR/ARP Annual Meeting
Naming Is Everything! the Cost of Inappropriate “Lupus Panel” Testing
Caleb Anderson¹, Roger Stitt ² and Robert O'Brian ¹, ¹Walter Reed National Military Medical Center, Bethesda, MD, ²US Army, Ft Eustis
Background/Purpose: Greater emphasis has been placed on cost saving measures due to ballooning healthcare cost in the U.S. ACGME now evaluates trainee ability to practice…
Abstract Number: 660 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Syndrome (APS) in Systemic Lupus Erythematosus (SLE) Leads to a More Severe Disease
Leyre Riancho-Zarrabeitia¹, Víctor M Martinez-Taboada ², Iñigo Rua Figueroa ³, Fernando Alonso ⁴, María Galindo ⁵, Juan Ovalles-Bonilla ⁶, Alejandro Olivé-Marqués ⁷, Antonio Fernández-Nebro ⁸, Jaime Calvo-Alen ⁹, Raul Menor Almagro ¹⁰, Eva Tomero-Muriel ¹¹, Esther Uriarte Isacelaya ¹², Alina Boteanu ¹³, Mariano Andrés ¹⁴, Mercedes Freire González ¹⁵, Gregorio Santos Soler ¹⁶, Esther Ruiz Lucea ¹⁷, Monica Ibañez Barcelo ¹⁸, Ivan Castellvi ¹⁹, Carles Galisteo ²⁰, Víctor Quevedo Vila ²¹, Enrique Raya ²², Javier Narváez ²³, Lorena Expósito ²⁴, José A Hernández-Beriain ²⁵, Loreto Horcada Rubio ²⁶, Elena Aurrecoechea ²⁷ and Jose Maria Pego-Reigosa ²⁸, ¹Hospital Sierrallana, Torrelavega, Spain, ²Hospital Valdecilla, Santander, ³Hospital Doctor Negrin, Las Palmas, ⁴Unidad Investigación SER, Madrid, Spain, ⁵Hospital 12 De Octubre, Madrid, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Hospital German Trias i Pujol, Badalona, Spain, ⁸Hospital Carlos Haya, Malaga, Spain, ⁹Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ¹⁰Hospital Universitario de Jerez, Puerto De Santa María, Spain, ¹¹Hospital Universitario La Princesa, Madrid, Spain, ¹²Hospital Universitario Donosti, San Sebastian, Spain, ¹³Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁴Hospital General Universitario de Alicante, Alicante, Spain, ¹⁵Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹⁶Hospital Marina Baixa, Villajoyosa, Spain, ¹⁷Hospital Universitario Basurto, Bilbao, Spain, ¹⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ¹⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²⁰Hospital Parc Taulí, Barcelona, Catalonia, Spain, ²¹Hospital Comarcal Monforte, Monforteº, Spain, ²²Hospital Universitario Clínico San Cecilio, Granada, Spain, ²³Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ²⁴Hospital Universitario de Canarias, Las Palmas, Spain, ²⁵Hospital Insular Universitario de Gran Canaria, Las Palmas, Spain, ²⁶Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, ²⁷Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²⁸Complexo Hospitalario Universitario, Vigo, Spain
Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in SLE patients. Our aim was to investigate the differences between SLE…
Abstract Number: 128 • 2019 ACR/ARP Annual Meeting
Metabolomics Analysis Identifies Biomarkers for APS and Suggests a Potential New Pathway Related to APS Pathogenesis
Chun Li ¹, Yu Zuo², Jason Knight ³, Juan Feng ⁴, Xian Wang ⁴, David Karp ⁵ and Zhanguo Li ⁶, ¹Peking Univerisity People's Hospital, Beijing, China (People's Republic), ²University of Texas Southwestern, Dallas, TX, ³Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁴Peking University School of Basic Medical Science, Beijing, China (People's Republic), ⁵UTSouthwestern Medical Center, Dallas, TX, ⁶People's Hospital, Beijing University Medical School, Beijing, China (People's Republic)
Background/Purpose: The metabolic disturbances that underlie antiphospholipid syndrome (APS) are currently unknown. The goal of this study was to utilize high-throughput metabolomics screening to identify…
Abstract Number: 1579 • 2019 ACR/ARP Annual Meeting
Presence of Antiphospholipid Antibodies in Patients with SLE and Venous Thromboembolic Events of African American and Caucasian Race
Elena Gkrouzman¹, Julia Davis-Porada ¹, Mary Peng ² and Kyriakos Kirou ², ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery, New York, NY
Background/Purpose: Risk of thrombosis is elevated in patients with systemic lupus erythematosus (SLE) compared to healthy individuals, especially during the first year after diagnosis. The…
Abstract Number: 129 • 2019 ACR/ARP Annual Meeting
Surface Proteins on Exosomes Derived from Plasma of APS Patients Indicate an Altered Immune, Cell Adhesion and Coagulation Profile
Ula Štok ¹, Elizabeta blokar ¹, Aleš Ambrožič ¹, Matija Tomsic ¹, Snezna Sodin-Semrl ², Saša Čučnik ¹ and Polona Žigon³, ¹Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia, ³Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by thromboses and/or obstetric complications in presence of antiphospholipid antibodies (aPL). Extracellular vesicles have been suggested to play a…
Abstract Number: 1746 • 2019 ACR/ARP Annual Meeting
Identifying Additional Risk Factors for Arterial and Venous Thrombosis Among Pediatric Antiphospholipid Antibodies Carriers
Elizabeth Sloan¹, Tracey Wright ¹ and Yu Zuo ², ¹University of Texas Southwestern, Texas Scottish Rite Hospital for Children, Children's Health, Dallas, TX, ²University of Texas Southwestern, Dallas, TX
Background/Purpose: Antiphospholipid antibodies (aPL) have been extensively reported in children; however, research on thrombotic risks associated with aPL among pediatric patients is scarce. Positive aPL…
Abstract Number: 130 • 2019 ACR/ARP Annual Meeting
Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Serum and Plasma Testing in a Real-World Clinical Setting
Michael Pham¹, Giovanni Orsolini ², Cynthia Crowson ³, Melissa Snyder ¹, Rajiv Pruthi ⁴ and Kevin Moder ⁵, ¹Mayo Clinic, Rochester, MN, ²University of Verona, Verona, Italy, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, ⁵Mayo Clinic Rochester, rochester, MN
Background/Purpose: Traditionally in ELISA detection of APS antibodies, the use of serum is thought to be preferable over plasma according to international consensus bodies. The…
Abstract Number: 1788 • 2019 ACR/ARP Annual Meeting
Anti-neutrophil Extracellular Trap (NET) Autoantibodies in Primary Antiphospholipid Syndrome
Yu Zuo¹, Srilakshmi Yalavarthi ², Kelsey Gockman ², David Karp ³, Quan-Zhen Li ⁴ and Jason Knight ⁵, ¹University of Texas Southwestern, Dallas, TX, ²University of Michigan, Ann Arbor, MI, ³UTSouthwestern Medical Center, Dallas, TX, ⁴Department of Immunology & Internal Medicine/University of Texas Southwestern Medical Center, Charleston, ⁵Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Neutrophil extracellular traps (NETs) are prothrombotic tangles of chromatin and microbicidal proteins ejected from neutrophils in response to a variety of stimuli. In antiphospholipid…
Abstract Number: 131 • 2019 ACR/ARP Annual Meeting
Anti-Phosphatidylserine Prothrombin Antibodies as a Predictor of the LAC in an All-Comer Population
Michael Pham¹, Giovanni Orsolini ², Cynthia Crowson ³, Melissa Snyder ¹, Rajiv Pruthi ⁴ and Kevin Moder ⁵, ¹Mayo Clinic, Rochester, MN, ²University of Verona, Verona, Italy, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, ⁵Mayo Clinic Rochester, rochester, MN
Background/Purpose: Anti-phosphatidylserine prothrombin antibodies (aPS-PT) are reported to be highly associated with the LAC. Some have suggested a clinically useful role for aPS-PT as a…
Abstract Number: 1791 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Antibody Profile Stability over Time: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Elena Gkrouzman¹, Ecem Sevim ², Jackie Finik ³, Danieli Andrade ⁴, Vittorio Pengo ⁵, Savino Sciascia ⁶, Maria Tektonidou ⁷, Amaia Ugarte ⁸, Cecilia Chighizola ⁹, H Michael Belmont ¹⁰, Laura Pérez Sánchez ¹¹, Lanlan Ji ¹², Paul Fortin ¹³, Maria Efthymiou ¹⁴, Guilherme De Jesus ¹⁵, David Branch ¹⁶, Cecilia Nalli ¹⁷, Michelle Petri ¹⁸, Ricard Cervera ¹⁹, Esther Rodriguez ²⁰, Jason Knight ²¹, Tatsuya Atsumi ²², Rohan Willis ²³, Maria Laura Bertolaccini ²⁴, Hannah Cohen ¹⁴, Jacob Rand ²⁵, Doruk Erkan ¹ and On Behalf Of APS ACTION ²⁶, ¹Hospital for Special Surgery, New York City, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, New York, NY, ⁴Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, ⁵Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ⁷First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁸Hospital Universitario Cruces, University of the Basque Country Autoimmune Diseases Research Unit, Department of Internal M edicine, BioCruces Health, Biscay, Spain, ⁹Rheumatology, Istituto Auxologico Italiano, University of Milan, Milan, Italy, ¹⁰NYU Langone Health, New York, NY, ¹¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ¹²Peking University First Hospital, Beijing, China (People's Republic), ¹³Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹⁴University College London, London, United Kingdom, ¹⁵Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁶University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁷Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹Hospital Clinic of Barcelona, Barcelona, Spain, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²²Hokkaido University, Sapporo, Japan, ²³Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, TX, ²⁴King's College London, London, United Kingdom, ²⁵Weill Cornell Medicine, New York, ²⁶APS ACTION, New York, NY
Background/Purpose: APS ACTION "Registry" was created to study long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with and without other systemic autoimmune diseases. Our primary…
Abstract Number: 132 • 2019 ACR/ARP Annual Meeting
Anti-phosphatidylserine/prothrombin Antibodies Confer a Distinctive Molecular Profile in Primary Antiphospholipid Syndrome Patients
Chary Lopez-Pedrera¹, Mª Ángeles Aguirre-Zamorano ², Laura Pérez-Sanchez ³, Alejandra Patiño-Trives ¹, Maria Luque-Tevar ¹, Alejandro Ibañez-Costa ¹, Ivan Arias de la Rosa ⁴, Maria del Carmen Abalos-Aguilera ¹, Lourdes Alacaide-Ruggiero ⁵, Rafaela Ortega ¹, Nuria Barbarroja ⁶, Eduardo Collantes-Estevez ⁴, Massimo Radin ⁷, Irene Cecchi ⁷, Savino Sciascia ⁸ and Carlos Perez-Sanchez ⁹, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵University of Cordoba, Cordoba, Spain, ⁶University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ⁷University of Turin, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ⁹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain
Background/Purpose: The clinical significance of non-canonical anti-phosphatidylserine/prothrombin (aPS/PT) antibodies in antiphospholipid syndrome (APS) is still controversial. This study assessed the prevalence of aPS/PT antibodies, their association with…
Abstract Number: 1793 • 2019 ACR/ARP Annual Meeting
Descriptive Analysis of Biopsy-proven Antiphospholipid Antibody-associated Nephropathy Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Maxime Taghavi¹, Medha Barbhaiya ², Maria Tektonidou ³, Paul Fortin ⁴, Danieli Andrade ⁵, Jason Knight ⁶, Bahar Artim-Esen ⁷, Tatsuya Atsumi ⁸, Hannah Cohen ⁹, Lanlan Ji ¹⁰, Savino Sciascia ¹¹, Surya Seshan ¹², Doruk Erkan ¹³ and on Behalf of APS ACTION ¹⁴, ¹Brugmann Hospital, Brugmann, Belgium, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁴Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ⁵Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, ⁶Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁷Istanbul University School of Medicine, Istanbul, Turkey, ⁸Hokkaido University, Sapporo, Japan, ⁹University College London, London, United Kingdom, ¹⁰Peking University First Hospital, Beijing, China (People's Republic), ¹¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ¹²Weill Cornell Medicine, New York, ¹³Hospital for Special Surgery, New York City, ¹⁴Hospital for Special Surgery, New York
Background/Purpose: Antiphospholipid antibody (aPL) nephropathy is a distinct entity that can be challenging to recognize and treat; it remains unknown if uniform pathologic criteria are…
Abstract Number: 135 • 2019 ACR/ARP Annual Meeting
Added Clinical Utility of Testing for Extra-Criteria Antibodies Specificities Beyond Sapporo and Sydney Criteria Recommendations
Savino Sciascia¹, Irene Cecchi ², Massimo Radin ², Elena Rubini ², Silvia Grazietta Foddai ², Dario Roccatello ², Chelsea Bentow ³, Andrea Seaman ³, Carlos Ramirez ³ and Michael Mahler ³, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³Inova Diagnostics, San Diego, CA
Background/Purpose: The laboratory diagnostics of antiphospholipid syndrome (APS) takes into account the persistent positivity for anticardiolipin (aCL) and/or anti-β2glycoprotein I (anti-β2GPI) antibodies and/or the presence…
Abstract Number: 1962 • 2019 ACR/ARP Annual Meeting
Whole Transcriptome Analysis Maps Proinflammatory and Procoagulant Pathways in aPL Treated HUVECs
Markos Patsouras ¹, Panagiota Karagianni ¹, Marios Agelopoulos ², Spyros Foutadakis ², Eirini Alexopoulou ² and Panagiotis Vlachoyiannopoulos³, ¹Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Greece, Athens, ²Biomedical Research Foundation, Academy of Athens, ATHENS, ³University General Hospital of Athens “Laiko”, Athens, Greece
Background/Purpose: Antiphospholipid syndrome is an autoimmune thrombophillia characterized by recurrent thromboembolism and or pregrancy morbidity in the presence of antiphospholipid antibodies (aPL), which recognize either…

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].